Clinical Efficacy of Huoxue Jiedu Runzao Formula and Its Effects on Biomarkers in Patients with Primary Sj?gren's Syndrome Complicated by Pulmonary Fibrosis
10.13359/j.cnki.gzxbtcm.2025.09.011
- VernacularTitle:活血解毒润燥方对原发性干燥综合征并发肺纤维化患者临床疗效及生物标志物的影响
- Author:
Feng GU
1
;
Bing ZHANG
;
Fengjin XU
Author Information
1. 衡水市人民医院,河北衡水 053000
- Keywords:
Huoxue Jiedu Runzao Formula;
primary Sj?gren's syndrome;
pulmonary fibrosis;
yin deficiency and fluid depletion syndrome;
inflammatory factors;
immunoglobulins;
pulmonary function;
clinical efficacy
- From:
Journal of Guangzhou University of Traditional Chinese Medicine
2025;42(9):2162-2169
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy of Huoxue Jiedu Runzao Formula(HJRF)and its impact on biomarkers in patients with primary Sj?gren's syndrome(pSS)complicated by pulmonary fibrosis(PF)presenting with yin deficiency and fluid depletion syndrome(YDFDS).Methods A prospective study was conducted on 134 pSS-PF patients with YDFDS treated at Harrison International Peace Hospital from January 2021 to January 2024.Patients were randomly assigned to the control group(n=67)or the observation group(n=67)using a random number table.The control group received oral use of hydroxychloroquine sulfate,while the observation group received hydroxychloroquine sulfate combined with HJRF,both groups were treated for 12 weeks.Changes in traditional Chinese medicine(TCM)syndrome scores,serum inflammatory factors[interleukin-4(IL-4),interleukin-6(IL-6),C-reactive protein(CRP)],immunoglobulin(Ig)levels,pulmonary function parameters[forced expiratory volume in one second(FEV1),forced vital capacity(FVC),diffusing capacity of the lung for carbon monoxide per unit alveolar volume(DLco/VA),total lung capacity(TLC)],EULAR Sj?gren's Syndrome Patient Reported Index(ESSPRI),EULAR Sj?gren's Syndrome Disease Activity Index(ESSDAI),and modified Medical Research Council(mMRC)dyspnea scale scores were observed before and after treatment.The clinical efficacy was evaluated in both groups.Results(1)After 12 weeks of treatment,the overall response rate in the observation group was 97.01％(65/67),while that in the control group was 83.58％(56/67).The intergroup comparison(by chi-square test)revealed that the efficacy of the observation group was significantly superior to that of the control group(P＜0.01).(2)After treatment,the TCM syndromes scores regarding to vexing heat in the chest,plams and soles,dryness of the mouth and throat,dry stools,dry and cracked tongue,dry and sore eyes,parotid swelling and pain,skin dryness and cracking,sticky mouth and eyes,fatigue and lassitude,and joint pain were all significantly reduced compared to those before treatment(P＜0.05).Additionally,the reduction in scores for all TCM syndromes except dry and cracked tongue in the observation group was significantly greater than that in the control group(P＜0.05 or P＜0.01).(3)After treatment,the serum IL-4,IL-6,and CRP levels in both groups decreased compared to those before treatment(P＜0.05),and the reduction in the observation group was significantly greater than that in the control group(P＜0.01).(4)After treatment,the FEV1,FVC,DLco/VA,TLC,and other lung function indicators in both groups of patients increased compared to those before treatment(P＜0.05),and the increase in the observation group was significantly greater than that in the control group(P＜0.01).(5)After treatment,serum IgA and IgG levels in both groups decreased compared to those before treatment(P＜0.05),and the reduction in the observation group was significantly greater than that in the control group(P＜0.01).(6)After treatment,the ESSPRI,ESSDAI,and mMRC scores in both groups decreased compared to those before treatment(P＜0.05),and the reduction in the observation group was significantly greater than that in the control group(P＜0.01).Conclusion Compared to conventional western therapy alone,HJRF combined with hydroxychloroquine sulfate more effectively alleviates TCM syndromes,reduces inflammatory and immunoglobulin levels,improves pulmonary function,mitigates pSS symptoms and disease activity,and enhances overall treatment efficacy.This provides a superior therapeutic strategy for pSS-PF patients with YDFDS.
